Rating Worth Mentioning: Is Citigroup Very Positive For Zimmer Biomet (ZBH) After Its Upgrade?

November 29, 2016 - By Darrin Black

Rating Worth Mentioning:  Is Citigroup Very Positive For Zimmer Biomet (ZBH) After Its Upgrade?

Zimmer Biomet (ZBH) Upgrade

In an analyst note issued on 29 November, Citigroup has raised Zimmer Biomet (ZBH) stock to a Neutral. ZBH’s old rating was Sell.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Out of 2 analysts covering Zimmer Biomet (ZBH), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $148.0 is the highest target while $130.0 is the lowest. The $139 average target is 34.39% above today’s ($103.43) stock price. Zimmer Biomet has been the topic of 2 analyst reports since November 1, 2016 according to StockzIntelligence Inc. The stock has “Outperform” rating given by RBC Capital Markets on Tuesday, November 1. As per Tuesday, November 1, the company rating was upgraded by Needham.

About 969,624 shares traded hands. Zimmer Biomet Holdings Inc (ZBH) has declined 11.48% since April 26, 2016 and is downtrending. It has underperformed by 16.74% the S&P500.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on January, 26. They expect $2.11 earnings per share, up 0.96% or $0.02 from last year’s $2.09 per share. ZBH’s profit will be $421.06M for 12.25 P/E if the $2.11 EPS becomes a reality. After $1.79 actual earnings per share reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts 17.88% EPS growth.

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has a market cap of $20.64 billion. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It has a 57.88 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Wsj.com which released: “Zimmer Biomet Cuts Forecasts” on October 31, 2016, also Forbes.com with their article: “Zimmer Biomet Holdings Becomes Oversold (ZBH)” published on November 22, 2016, Reuters.com published: “BRIEF-Seikagaku signs exclusive distribution agreement with Zimmer Biomet …” on November 08, 2016. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Prnewswire.com and their article: “ZIMMER BIOMET (ZBH) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP …” published on November 02, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: November 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>